5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Acute Myeloid Leukemia Market is segmented by Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, and Other Chemotherapies) and Geography.
Fastest Growing Market:
The global acute myeloid leukemia market is expected to grow with a CAGR of 14.0% over the forecasted period. The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
The American Cancer Society’s estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. These statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.
In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.
This report estimates the global acute myeloid leukemia market and includes a detailed analysis of cytarabine, anthracycline drugs, and daunomycin.
Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.
Report scope can be customized per your requirements. Click here.
In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.
Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
To understand key trends, Download Sample Report
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.
To understand geography trends, Download Sample Report.
The acute myeloid leukemia market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new techniques with good results. Companies, like Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation), hold substantial shares in the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.2.3 Increasing Investments in R&D
4.3 Market Restraints
4.3.1 Stringent Regulations on Drugs
4.3.2 Complications Related to Chemotherapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1.2 Anthracycline Drugs
5.1.3 Alkylating Agents
5.1.5 Tyrosine Kinase Inhibitors
184.108.40.206 Dasatinib (Sprycel)
220.127.116.11 Imatinib (Gleevec)
5.1.6 Hormonal Therapy
5.1.7 Other Chemotherapies
5.2.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.2.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.2.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Celegene Corporation
6.1.2 Novartis AG
6.1.3 Genmab AS
6.1.4 Eisai Co. Ltd
6.1.5 Sanofi-Aventis (Genzyme Corporation)
6.1.6 Teva Pharmaceutical (Cephalon Inc.)
6.1.7 Pfizer Inc.
6.1.8 Bristol-Myers Squibb Company
6.1.9 Sunesis Pharmaceuticals Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments